-
PRM-151 Is Slowing Disability Progression Up To 76 Weeks In IPF Patients
Director of Multichannel Content for Pulmonary Fibrosis News, Michael Morale, discusses how a study is showing that the investigational therapy PRM-151 is slowing disability progression up to 76 weeks in IPF patients.
What are your thoughts on this news?
Sorry, there were no replies found.
Log in to reply.